Evidence map›Paper›PMID 36493798›Full record

ArticleLeukemia & lymphoma2023

Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with

Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory M Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jan Philipp BewersdorfLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3352-0902
Kishan K PatelDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
George GoshuaHematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Rory M ShallisHematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-8542-2944
Nikolai A PodoltsevHematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Maximilian StahlDepartment of Medical Oncology, Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Eytan M SteinLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Scott F HuntingtonHematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Amer M ZeidanHematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016359
6 · The paper itself

Abstract

Ivosidenib + azacitidine (IVO/AZA) is approved in the United States for newly diagnosed, older or intensive chemotherapy-ineligible patients with

Indexed as

AzacitidineLeukemia, Myeloid, AcuteCost-Benefit AnalysisGlycineHumansIsocitrate DehydrogenasePyridinesQuality-Adjusted Life YearsUnited StatesAzacitidineGlycineIDH1 protein, humanIsocitrate DehydrogenaseivosidenibPyridinesAcute myeloid leukemiaAMLazacitidinecost-effectivenessivosidenib

Identifiers

PMID36493798
PMCPMC9957935

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.